Sakar Healthcare Ltd reported a 74% rise in net profit to ₹3048.46 lakh for the financial year ended March 31, 2026, compared to ₹1750.20 lakh in the previous year. Revenue from operations increased to ₹25173.60 lakh from ₹17758.47 lakh in FY25, driven by the manufacturing of pharmaceutical products including liquid orals, tablets, and injections.

The Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026, at a meeting held on May 12, 2026. The statutory auditors, M/s. J. S. Shah & Co., issued an unmodified opinion on the financial results. The company clarified that there was no change in the financial figures or disclosures submitted earlier to the exchange, following an observation from the National Stock Exchange of India Limited.

For the quarter ended March 31, 2026, the company recorded a profit of ₹1102.43 lakh, up from ₹576.11 lakh in the corresponding quarter of the previous year. Revenue for the quarter stood at ₹7109.70 lakh. Earnings per share (EPS) for the year increased to ₹13.70 from ₹7.97 in the previous year.

Financial Performance

The company's total comprehensive income for the year rose to ₹3037.77 lakh from ₹1738.49 lakh in FY25. Total assets as of March 31, 2026, stood at ₹48109.45 lakh, compared to ₹41534.62 lakh a year ago. The company's equity reserves increased to ₹30228.78 lakh from ₹26073.12 lakh.

Corporate Governance

The Board appointed M/s. Kashyap R. Mehta & Partners, Company Secretaries, as the new secretarial auditors to fill a casual vacancy caused by the resignation of M/s. Nishant Pandya & Associates. The new auditors will hold office until the date of the ensuing Annual General Meeting. The consolidated financial results remain identical to the standalone results as the subsidiary, Sakar Oncology Private Limited, did not undertake any business transactions during the reporting period.

Sakar Healthcare has reported its audited consolidated financial results for the quarter and year ended March 31, 2026, recording a significant increase in annual net profit. The company's net profit for the fiscal year rose to 3,048.46 lakhs rupees from 1,750.20 lakhs rupees in the previous year, driven by robust operational performance and improved efficiency across its pharmaceutical manufacturing segment. For the fourth quarter, net profit stood at 1,102.43 lakhs rupees, nearly doubling from 576.11 lakhs rupees year-on-year. Following the results announcement, the company has made available the audio recording and transcript of the conference call held on May 15, 2026, on its website.

FY26 Financial Performance

The annual results demonstrate strong year-on-year growth across key financial metrics. Revenue from operations for the year increased to 25,173.60 lakhs rupees from 17,758.47 lakhs rupees in the prior year, reflecting 42% YoY growth. EBITDA for FY26 stood at 6,888.82 lakhs rupees, up 39% YoY, with an EBITDA margin of 27%. The company also reported a basic earnings per share (EPS) of 13.70 rupees for the year, compared to 7.97 rupees in FY25.

Q4 Performance

For the fourth quarter ended March 31, 2026, the company delivered a strong performance with revenue climbing to 7,109.70 lakhs rupees from 5,024.18 lakhs rupees in the same quarter of the previous year, a 42% YoY increase. EBITDA for the quarter increased to 2,623.57 lakhs rupees, up 67% YoY, with EBITDA margins expanding to 37% from 31% in the corresponding prior-year quarter. Net profit for the quarter stood at 1,102.43 lakhs rupees, nearly doubling from 576.11 lakhs rupees year-on-year, with PAT margin improving to 16% from 11%.

Business Highlights

The company reported significant operational progress during Q4 and FY26, particularly within its oncology division. Key business milestones include:

• Completed over 60 business contracts with oncology products, with over 35 discussions ongoing
• Of 250 dossiers shared globally, 125 have been submitted and 12 have received Marketing Authorizations from Regulatory Authorities
• 21 of 32 developed oncology product dossiers have been shared; of which 11 dossiers have received approval, covering products including Abiraterone, Imatinib, Tamoxifen, Capecitabine, Gemcitabine, Carboplatin, Irinotecan, and Docetaxel
• Technology Transfer projects with oncology products are ongoing for Accord-Intas, Torrent-UK & Germany, Emcure, Glenmark, and Zydus, of which 4 have received site variation approvals (2 each in the UK and EU)

Management Commentary

Commenting on the results, Mr. Sanjay Shah, Managing Director, said: "Q4 marked another meaningful step forward for Sakar Healthcare, with strong year-on-year growth and improved profitability reflecting steady execution across the business. The quarter also underlined the increasing importance of oncology in our overall growth strategy, as the division continues to scale up and gradually shape the company's future growth profile. This progress is being supported by a widening product base, improving market reach, and a growing export opportunity across key markets. As approvals continue to convert into launches and commercial supplies, we believe the business is entering a stronger and more sustainable growth phase. The oncology platform, in particular, remains well placed to benefit from rising volumes, better capacity utilisation, and operating leverage as scale improves."

FY27 Outlook

Looking ahead, Sakar Healthcare anticipates FY27 to be an important year for the company, with export momentum expected to strengthen further and oncology volumes continuing to ramp up, supporting the next phase of growth. The company's focus on expanding its export footprint alongside scaling up its oncology segment is expected to further underpin its growth trajectory. Management indicated that oncology exports are gaining traction, with the oncology division contributing around 38% of total revenues in FY26. The company expects exports to become the dominant contributor over the medium term as more approvals convert into commercial supplies.

Corporate Governance

The Board of Directors approved the audited standalone and consolidated financial results at its meeting held on May 12, 2026. Additionally, the board appointed M/s. Kashyap R. Mehta & Partners as Secretarial Auditors to fill a casual vacancy. The statutory auditors, M/s. J. S. Shah & Co., issued an unmodified opinion on the financial results. The audio recording and transcript of the conference call held on May 15, 2026, has been made available on the company's website.